An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Tecemotide (Primary)
- Indications Myeloma; Non-small cell lung cancer
- Focus Adverse reactions; Expanded access
- Sponsors Merck KGaA
- 03 Aug 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 23 Nov 2014 Planned End Date changed from 1 Dec 2019 to 1 May 2015 as reported by ClinicalTrials.gov.
- 23 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.